Brief: Hybrigenics FY Operating Loss Widens To 7.4 Million Euros, Presents Update On Inecalcitol Clinical Studies

Aton SA

26/04/2018 20:20

April 26 (Reuters) - HYBRIGENICS SA  ALHYG.PA :
    * FY REVENUE EUR 0 MILLION VERSUS EUR 1.5 MILLION (RESTATED)
YEAR
AGO
    * FY OPERATING LOSS EUR 7.4 MILLION VERSUS LOSS OF EUR 4.0
MILLION
(RESTATED) YEAR AGO
    * FY NET LOSS EUR 8.0 MILLION VERSUS LOSS OF EUR 5.3 MILLION
(RESTATED) YEAR AGO
    * END-DEC CASH POSITION OF CONTINUED ACTIVITIES EUR 7.0
MILLION
VERSUS EUR 8.5 MILLION (RESTATED) YEAR AGO
    * 87 PATIENTS RECRUITED IN INECALCITOL PHASE II ACUTE
MYELOID
LEUKEMIA STUDY
    * PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL SHOWS
ABILITY TO DECREASE RESIDUAL CML DISEASE
    * PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL
EFFECTS
BEYOND USUAL EFFECTS OF IMATINIB
    * DECISION ON LAUNCH OF NEXT CLINICAL TRIAL OF INECALCITOL
IN CML
TO BE MADE AFTER AML STUDY RESULTS
    * PHASE II AML INECALCITOL STUDY: TO ENROL 110 PATIENTS
BEFORE
END-2018, FINAL RESULTS EXPECTED IN 2019

Source text: https://bit.ly/2HAcCss
Further company coverage:  ALHYG.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))